Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 218

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Phenformin enhances the therapeutic benefit of BRAF V600E inhibition in melanoma

Open access
Yuan, Ping, Ito, Koichi, Perez-Lorenzo, Rolando, Del Guzzo, Christina, Lee, Jung Hyun, Shen, Che-Hung, Bosenberg, Marcus W., McMahon, Martin, Cantley, Lewis C., Zheng, Bin·2013·Proceedings of the National Academy of Sciences

Abstract

Significance: Inhibitors of BRAF protein kinase, such as Vemurafenib and Dabrafenib, have shown remarkable antitumor activity in patients with BRAF mutant melanoma. However, most of the patients developed drug resistance during the course of treatment, leading to resumed tumor growth. This drug resistance challenge underscores the need to improve on current BRAF-targeted therapy. In this study, we have shown that phenformin, a biguanide used for treating type 2 diabetes, enhances the antitumor activities of BRAF inhibitors in both cultured melanoma cells and a genetically engineered BRAF V600E -driven mouse model of melanoma. Our preclinical findings suggest that combining phenformin with a BRAF inhibitor may be a more effective treatment than a single-agent BRAF inhibitor for treating patients with melanoma whose tumor harbor BRAF mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1317577110

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 218

Metadata

Authors
Yuan, P., Ito, K., Perez-Lorenzo, R., Del Guzzo, C., Lee, J. H., Shen, C.-H., Bosenberg, M. W., McMahon, M., Cantley, L. C., & Zheng, B.
Venue
Proceedings of the National Academy of Sciences
Published
2013-10-21
Volume
110
Issue
45
Pages
18226-18231
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2101774229
Cited by
218
References
9
FWCI
8.20
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phenformin enhances the therapeutic benefit of BRAF V600E inhibition in melanoma. https://app.cochat.ai/papers/10.1073/pnas.1317577110
The paper
Yuan, P., Ito, K., Perez-Lorenzo, R., Del Guzzo, C., Lee, J. H., Shen, C.-H., Bosenberg, M. W., McMahon, M., Cantley, L. C., & Zheng, B. (2013). Phenformin enhances the therapeutic benefit of BRAF V600E inhibition in melanoma. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1317577110

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.